{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T06:08:15Z","timestamp":1784354895347,"version":"3.55.0"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2002,3,1]],"date-time":"2002-03-01T00:00:00Z","timestamp":1014940800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2002,3,1]],"date-time":"2002-03-01T00:00:00Z","timestamp":1014940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"published-print":{"date-parts":[[2002,3]]},"DOI":"10.1023\/a:1014492517088","type":"journal-article","created":{"date-parts":[[2002,12,28]],"date-time":"2002-12-28T15:35:40Z","timestamp":1041089740000},"page":"29-40","source":"Crossref","is-referenced-by-count":1,"title":["Current problems and needs in the treatment of pT1 G3 bladder carcinoma"],"prefix":"10.1007","volume":"33","author":[{"given":"Francisco Jose Mart\u00ednez","family":"Portillo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Alken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"387074_CR1","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/00005392-199707000-00017","volume":"156","author":"MS Cookson","year":"1997","unstructured":"Cookson MS, Herr HW, Zhang ZF, Soloway S, Sogani PC, Fair WR. The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol 1997; 156: 62\u201367.","journal-title":"J Urol"},{"key":"387074_CR2","doi-asserted-by":"crossref","unstructured":"Heney NM. Natural history of superficial bladder cancer. In: Lamm DL, ed. Superficial bladder cancer. Urol Clin North Am 1992; 19: 429\u2013433.","DOI":"10.1016\/S0094-0143(21)00411-0"},{"key":"387074_CR3","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1002\/(SICI)1097-0142(19990915)86:6<910::AID-CNCR3>3.0.CO;2-G","volume":"86","author":"L Cheng","year":"1999","unstructured":"Cheng L, Bostwick DG. Progression of T1 tumors: Better staging or better biology? Reply. Cancer 1999; 86: 910\u2013912.","journal-title":"Reply. Cancer"},{"issue":"16","key":"387074_CR4","first-page":"122","volume":"3","author":"T Otto","year":"1994","unstructured":"Otto T, R\u00fcbben H. Management of T1 G3 bladder carcinomas. European Urology Update Series 1994; 3(16): 122\u2013127.","journal-title":"European Urology Update Series"},{"key":"387074_CR5","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0022-5347(05)67975-X","volume":"163","author":"F Millan-Rodriguez","year":"2000","unstructured":"Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, Palou J, Vicente-Rodriguez J. Multivariate analysis of the prognostic factors of primary superficial bladder cancer. J Urol 2000; 163: 73\u201378.","journal-title":"J Urol"},{"key":"387074_CR6","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/S0022-5347(17)36282-1","volume":"149","author":"RA Thompson Jr","year":"1993","unstructured":"Thompson RA Jr, Campbell EW Jr, Kramer HC, Jacobs SC, Naslund MJ. Late invasive recurrence despite long-term surveillance for superficial bladder cancer. J Urol 1993; 149: 1010\u20131014.","journal-title":"J Urol"},{"key":"387074_CR7","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/00005392-199707000-00017","volume":"158","author":"HW Herr","year":"1997","unstructured":"Herr HW, Cookson MS, Zhang ZF et al. The treated natural history of high risk superficial bladder cancer: Fifteen year outcome. J Urol 1997; 158: 62\u201376.","journal-title":"J Urol"},{"issue":"Suppl.","key":"387074_CR8","first-page":"669A","volume":"163","author":"Y Yan","year":"2000","unstructured":"Yan Y, Andriole GL, Diaz N, Hudson ML, Swanson PE, Humphrey PA. Use of clinicopathological and immunohistochemical factors to predict multiple recurrences among patients with superficial TCC of the bladder. J Urol 2000; 163(Suppl.): 150: 669A.","journal-title":"J Urol"},{"issue":"Suppl.","key":"387074_CR9","first-page":"A 671","volume":"163","author":"R Tiguert","year":"2000","unstructured":"Tiguert R, Gheiler EL, Duncan R, SolowayMS. Tumour recurrence and progression following conservative management for T1G3 transitional cell carcinoma of the bladder. J Urol 2000; 163(Suppl.): A 671.","journal-title":"J Urol"},{"key":"387074_CR10","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S0022-5347(01)62047-0","volume":"161","author":"HW Herr","year":"1999","unstructured":"Herr HW, Bajorin DF, Scher HI, Cordon-Cardo C, Reuter VE. Can p53 help select patients with invasive bladder cancer for bladder preservation? J Urol 1999; 161: 20\u201323.","journal-title":"J Urol"},{"key":"387074_CR11","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0094-0143(05)70236-6","volume":"27","author":"AF. Olumi","year":"2000","unstructured":"Olumi AF. A critical analysis of the sue of p53 as a marker for management of bladder cancer. Urol Clin North Am 2000; 27: 75\u201382.","journal-title":"Urol Clin North Am"},{"key":"387074_CR12","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/jnci\/85.1.53","volume":"85","author":"AS Sarkis","year":"1993","unstructured":"Sarkis AS, Dalbagni G, Cordon-Cardo C, Zhang ZF, Sheinfeld J, Fair WR, Herr HW, Reuter VE. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: A marker for disease progression. J Natl Cancer Inst 1993; 85: 53\u201359.","journal-title":"J Natl Cancer Inst"},{"key":"387074_CR13","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/S0959-8049(99)00325-1","volume":"36","author":"G Steiner","year":"2000","unstructured":"Steiner G, Bierhoff E, Schmidt D, Leissner J, Wolf HK, Albers P. p53 immunoreactivity in biopsy specimens of T1 G3 transitional cell carcinoma of the bladder - a helpful parameter in guiding the decision for or against cystectomy. Eur J Cancer 2000; 36: 610\u2013614.","journal-title":"Eur J Cancer"},{"key":"387074_CR14","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S0022-5347(17)69924-5","volume":"55","author":"HJ Jewett","year":"1946","unstructured":"Jewett HJ, Strong GH. Infiltrating carcinoma of the bladder: Relation of depth and penetration of the bladder wall to incidence of local extension and metastases. J Urol 1946; 55: 366.","journal-title":"J Urol"},{"key":"387074_CR15","first-page":"1035","volume":"11","author":"CE Platz","year":"1996","unstructured":"Platz CE, Cohen MB, Jones MP, Olsen DB, Lynch CF. Is microstaging of early invasive cancer of the urinary bladder possible or useful? Mod Pathol 1996; 11: 1035\u20131039.","journal-title":"Mod Pathol"},{"issue":"Suppl.","key":"387074_CR16","doi-asserted-by":"crossref","first-page":"315A","DOI":"10.1097\/00005392-199904020-00264","volume":"161","author":"A Weizer","year":"1999","unstructured":"Weizer A, Green A, Shaw C, Wheeler T, Lerner S. Risk assessment of T1 transitional cell carcinoma of the bladder using p53 immunohistochemistry and pathologic substaging. J Urol 1999; 161 (Suppl.): 315A.","journal-title":"J Urol"},{"key":"387074_CR17","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1002\/(SICI)1097-0142(19990915)86:6<1035::AID-CNCR20>3.0.CO;2-D","volume":"86","author":"L Cheng","year":"1999","unstructured":"Cheng L, Weaver AL, Neumann RM, Scherer BG, Bostwick DG. Substaging of T1 bladder carcinoma based on the depth of invasion as measured by micrometer: a new proposal. Cancer 1999; 86: 1035\u20131043.","journal-title":"Cancer"},{"key":"387074_CR18","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1200\/JCO.1999.17.10.3182","volume":"17","author":"L Cheng","year":"1999","unstructured":"Cheng L, Neumann RM, Weaver AL, Spotts BE, Bostwick DG. Predicting cancer progression in patients with stage T1 bladder carcinoma. J Clin Oncol 1999a; 17: 3182\u20133187.","journal-title":"J Clin Oncol"},{"key":"387074_CR19","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/S1078-1439(96)00050-6","volume":"2","author":"HW. Herr","year":"1996","unstructured":"Herr HW. Uncertainty and outcome of invasive bladder tumors. Urol Oncol 1996; 2: 92\u201395.","journal-title":"Urol Oncol"},{"key":"387074_CR20","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/00005392-199907000-00018","volume":"162","author":"HW. Herr","year":"1999","unstructured":"Herr HW. The value of a second transurethral resection in evaluating patients with bladder tumors. J Urol 1999; 162: 74\u201376.","journal-title":"J Urol"},{"issue":"Suppl.2","key":"387074_CR21","first-page":"A 441","volume":"37","author":"H Schwaibold","year":"2000","unstructured":"Schwaibold H, Treiber U, K\u00fcbler H, Leyh H, Hartung R. Significance of second transurethral resection for T1 bladder cancer. Eur Urol 2000; 37(Suppl. 2): A 441.","journal-title":"Eur Urol"},{"key":"387074_CR22","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1055\/s-2008-1058226","volume":"25","author":"KU K\u00f6hrmann","year":"1994","unstructured":"K\u00f6hrmann KU, Woeste M, Kappes J, Rassweiler J, Alken P. Der Wert der transurethralen Nachresektion beim oberfl\u00e4chlichen Harnblasenkarzinom. Akt Urol 1994; 25: 208\u2013213.","journal-title":"Akt Urol"},{"issue":"Suppl.2","key":"387074_CR23","first-page":"A 442","volume":"37","author":"L Schips","year":"2000","unstructured":"Schips L, Augustin H, Zigeuner R, Trummer H, Pummer K, Hubmer G. Is a second transurethral resection (TUR) justified in patients with newly diagnosed superficial bladder cancer? Eur Urol 2000; 37(Suppl. 2): A 442.","journal-title":"Eur Urol"},{"issue":"Suppl.2","key":"387074_CR24","first-page":"A 440","volume":"37","author":"JJ Rassweiler","year":"2000","unstructured":"Rassweiler JJ, Rahm HJ, Yaser AS, Hatzinger M. Fluorescence aided transurethral resection of superficial bladder cancer - does it improve the quality of TUR? Eur Urol 2000; 37(Suppl. 2): A 440.","journal-title":"Eur Urol"},{"key":"387074_CR25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000471649","volume":"20","author":"HW Herr","year":"1991","unstructured":"Herr HW, Jakse G. pT1 bladder cancer. Eur Urol 1991; 20: 1\u20138.","journal-title":"Eur Urol"},{"key":"387074_CR26","first-page":"2","volume":"30","author":"H R\u00fcbben","year":"1991","unstructured":"R\u00fcbben H, Jocham D. Therapy of superficial bladder carcinoma. Urologe A 1991; 30: 2\u20139.","journal-title":"Urologe A"},{"key":"387074_CR27","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S0022-5347(17)40575-1","volume":"141","author":"HW Herr","year":"1989","unstructured":"Herr HW, Badalament RA, Amato DA, Laudone VP, Fair WR, Whitmore WF Jr. Superficial bladder cancer treated with bacillus Calmette-Guerin: a multivariate analysis to factors affecting tumor progression. J Urol 1989; 141: 22\u201329.","journal-title":"J Urol"},{"key":"387074_CR28","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1464-410X.1982.tb13538.x","volume":"54","author":"NM Heney","year":"1982","unstructured":"Heney NM, Nocks BN, Daly JJ, Prout GR Jr, Newall JB, Griffin PP, Perrone TL, Szyfelbein WA. Ta and T1 bladder cancer: location, recurrence and progression. Br J Urol 1982; 54: 152\u2013156.","journal-title":"Br J Urol"},{"key":"387074_CR29","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0022-5347(17)43864-X","volume":"137","author":"G Jakse","year":"1987","unstructured":"Jakse G, Loidl W, Seeber G, Hofst\u00e4dter F. Stage T1 grade 3 transitional cell carcinoma of the bladder: An unfavourable tumor? J Urol 1987; 137: 39\u201343.","journal-title":"J Urol"},{"key":"387074_CR30","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1159\/000020018","volume":"36","author":"E Zungri","year":"1999","unstructured":"Zungri E, Mart\u00ednez L, da Silva EA, Pesqueira D, de la Funete Buceta A, Pereiro B: T1 G3 bladder cancer. Management with transurethral resection only. Eur Urol 1999; 36: 380\u2013385.","journal-title":"Eur Urol"},{"key":"387074_CR31","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/S0022-5347(17)37779-0","volume":"146","author":"R Kl\u00e4n","year":"1991","unstructured":"Kl\u00e4n R, Loy V, Huland H. Residual tumor discovered in routine second transurethral resection in patients with stage T1 transitional cell carcinoma of the bladder. J Urol 1991; 146: 316\u2013318.","journal-title":"J Urol"},{"issue":"Suppl.","key":"387074_CR32","first-page":"59","volume":"31A","author":"TA V\u00f6geli","year":"1992","unstructured":"V\u00f6geli TA, Marx G, Ackermann R. Zur Notwendigkeit der Nachresektion beim urothelialen Blasenkarzinom als Kontrolle der Erstresektion. Urologe A1992; (Suppl.): 31 A 59.","journal-title":"Urologe"},{"key":"387074_CR33","series-title":"MEDICINE Publishing Foundation Series","first-page":"1","volume-title":"Optimal therapy for patients with high-risk superficial bladder cancer - controversy and consensus","author":"DE. Neal","year":"1997","unstructured":"Neal DE. Pathological aspects of pT1G3 urothelial carcinoma and carcinoma in situ. In: B\u00f6hle, Jocham, eds. Optimal therapy for patients with high-risk superficial bladder cancer - controversy and consensus (MEDICINE Publishing Foundation Series 37). The Medicine Group (Education), Oxford, 1997: 1\u201310."},{"key":"387074_CR34","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/j.1464-410X.1994.tb07487.x","volume":"73","author":"JA Witjes","year":"1994","unstructured":"Witjes JA, Kiemeney LA, Schaafsma HE, Debruyne FM, the members of the Dutch Southeast Cooperative Urological Group. The influence of review pathology on study outcome of a randomized multicentre superficial bladder cancer trial. Br J Urol 1994; 73: 172\u2013176.","journal-title":"Br J Urol"},{"key":"387074_CR35","first-page":"153","volume":"4","author":"MS. Soloway","year":"1993","unstructured":"Soloway MS. The evaluation and follow-up of patients with Ta, Tcis and T1 bladder cancer. World J Urol 1993; 4: 153\u2013155.","journal-title":"World J Urol"},{"key":"387074_CR36","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/1097-0142(19950901)76:5<833::AID-CNCR2820760518>3.0.CO;2-M","volume":"76","author":"JA Freeman","year":"1995","unstructured":"Freeman JA, Esrig D, Stein JP, Simoneu AR, Skinner EC, Chen SC, Groshen S, Lieskovsky G, Boyd SD, Skinner DG. Radical cystectomy for high risk patients with superficial bladder cancer in the era of orthotopic urinary reconstruction. Cancer 1995; 76: 833\u2013839.","journal-title":"Cancer"},{"key":"387074_CR37","first-page":"154","volume":"15","author":"D Esrig","year":"1997","unstructured":"Esrig D, Freeman JA, Stein JP, Skinner DG. Early cystectomy for clinical stage T1 transitional cell carcinoma of the bladder. Seminol Urol Oncol 1997; 15: 154\u2013160.","journal-title":"Seminol Urol Oncol"},{"key":"387074_CR38","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1002\/(SICI)1097-0142(19990915)86:6<908::AID-CNCR2>3.0.CO;2-E","volume":"86","author":"HW Herr","year":"1999","unstructured":"Herr HW, Reuter VE. Progression of T1 bladder tumors. Better staging or better biology. Editorial comment. Cancer 1999; 86: 908\u2013910.","journal-title":"Cancer"},{"key":"387074_CR39","first-page":"254","volume":"4","author":"HW Herr","year":"1990","unstructured":"Herr HW, Jakse G, Sheinfeld J. The T1 bladder tumor. Sem Urol 1990; 4: 254\u2013261.","journal-title":"Sem Urol"},{"key":"387074_CR40","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1046\/j.1464-410x.1999.00370.x","volume":"84","author":"HW. Herr","year":"1998","unstructured":"Herr HW. The natural history of a T1 bladder cancer: life-long tumor diathesis. Br J Urol 1998; 84: 1102\u20131103.","journal-title":"Br J Urol"},{"key":"387074_CR41","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1046\/j.1464-410x.1999.00370.x","volume":"84","author":"HW. Herr","year":"1999","unstructured":"Herr HW. The natural history of a T1 bladder cancer: life-long tumor diathesis. BJU Int 1999a; 84: 1102\u20131103.","journal-title":"BJU Int"},{"key":"387074_CR42","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0022-5347(17)37706-6","volume":"146","author":"S Kaubisch","year":"1991","unstructured":"Kaubisch S, Lum BL, Reese J, Freiha F, Torti FM. Stage T1 bladder cancer: Grade is the primary determinant for risk of muscle invasion. J Urol 1991; 146: 28\u201331.","journal-title":"J Urol"},{"key":"387074_CR43","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1046\/j.1464-410X.1997.00431.x","volume":"80","author":"HW. Herr","year":"1997","unstructured":"Herr HW. Tumour progression and survival in patients with T1G3 bladder tumours: 15-year outcome. Br J Urol 1997; 80: 762\u2013765.","journal-title":"Br J Urol"},{"key":"387074_CR44","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1056\/NEJM199110243251703","volume":"325","author":"DL Lamm","year":"1991","unstructured":"Lamm DL, Blumenstein BA, Crawford ED, Montie JE, Scardino P, Grossman HB, Stanisic TH, Smith JA Jr, Sullivan J, Sarosdy MF, Crissman JD, Coltman CA. A randomized trial of intravesical doxirubicin and immunotherapy with bacille Calmette-Gu\u00e9rin for transitional cell carcinoma of the bladder. N Engl J Med 1991; 325: 1205\u20131209.","journal-title":"N Engl J Med"},{"key":"387074_CR45","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1200\/JCO.1995.13.6.1404","volume":"13","author":"HW Herr","year":"1995","unstructured":"Herr HW, Schwalb DM, Zhang ZF, Sogani PC, Fair WR, Whitmore WF Jr, Oettgen HF. Intravesical bacillus Calmette-Gu\u00e9rin therapy prevents tumor progression and death from superficial bladder cancer. 10-year follow-up up a perspective randomized trial. J Clin Oncol 1995; 13: 1404\u20131408.","journal-title":"J Clin Oncol"},{"key":"387074_CR46","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1016\/S0022-5347(05)68208-0","volume":"162","author":"JA Smith Jr","year":"1999","unstructured":"Smith Jr. JA, Labasky RF, Cockett ATK, Fracchia JA, Montie JE, Rowland RG. Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1 and Tis). J Urol 1999; 162: 1697\u20131701.","journal-title":"J Urol"},{"key":"387074_CR47","first-page":"384","volume":"36","author":"E. Solsona Narb\u00f3n","year":"1999","unstructured":"Solsona Narb\u00f3n E. Editorial comment. Eur Urol 1999; 36: 384\u2013385.","journal-title":"Eur Urol"},{"key":"387074_CR48","first-page":"4347","volume":"51","author":"GM Wientjes","year":"1991","unstructured":"Wientjes GM, Dalton JT, Badalament RA, Drago JR, Au JL. Bladder wall penetration of intravesical mitomycin C in dogs. Cancer Res 1991; 51: 4347\u20134354.","journal-title":"Cancer Res"},{"key":"387074_CR49","first-page":"5144","volume":"51","author":"JT Dalton","year":"1992","unstructured":"Dalton JT, Wientjes GM, Badalament RA, Drago JR, Au JL. Pharmacokinetics of intravesical mitomycin C in superficial bladder cancer patients. Cancer Res 1992; 51: 5144\u20135152.","journal-title":"Cancer Res"},{"key":"387074_CR50","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0022-5347(17)39365-5","volume":"144","author":"A B\u00f6hle","year":"1990","unstructured":"B\u00f6hle A, Gerdes J, Ulmer AJ, Hofstetter AG, Flad HD. Effects of local bacillus Calmette-Gu\u00e9rin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall. J Urol 1990; 144: 53\u201358.","journal-title":"J Urol"},{"key":"387074_CR51","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/S0022-5347(17)35941-4","volume":"150","author":"A B\u00f6hle","year":"1993","unstructured":"B\u00f6hle A, Thanh\u00e4user A, Ulmer AJ, Ernst M, Flad HD, Jocham D. Dissecting the immunobiological effects of bacillus Calmette-Gu\u00e9rin (BCG) in vitro: Evidence of a distinct BCGactivated killer (BAK) cell phenomen. J Urol 1993; 150: 1932\u20131937.","journal-title":"J Urol"},{"key":"387074_CR52","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1200\/JCO.1988.6.9.1450","volume":"6","author":"HW Herr","year":"1988","unstructured":"Herr HW, Laudone VP, Badalament RA, Oettgen HF, Sogani PC, Freedman BD, Melamed MR, Whitmore WF, Jr. Bacillus Calmette-Gu\u00e9rin therapy alters the progression of superficial bladder cancer. J Clin Oncol 1988; 6: 1450\u20131455.","journal-title":"J Clin Oncol"},{"key":"387074_CR53","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S0090-4295(99)00116-8","volume":"54","author":"R Hurle","year":"1999","unstructured":"Hurle R, Losa A, Manzetti A, Lembo A. Intravesical Bacille Calmette-Gu\u00e9rin in stage T1 grade 3 bladder cancer therapy: a 7-year follow-up. Urology 1999; 54: 258\u2013263.","journal-title":"Urology"},{"key":"387074_CR54","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1159\/000020171","volume":"37","author":"AV Bono","year":"2000","unstructured":"Bono AV, Lovisolo JA, Saredi G. Transurethral resection and sequential chemo-Immunoprophylaxis in primary T1G3 bladder cancer. Eur Urol 2000; 37: 478\u2013483.","journal-title":"Eur Urol"},{"issue":"Suppl.","key":"387074_CR55","first-page":"A 673","volume":"163","author":"DL Lamm","year":"2000","unstructured":"Lamm DL, Riggs DL, Bugaj M, Hobbs G. Intravesical prophylaxis in bladder cancer: a meta-analysis. J Urol 2000; 163(Suppl.): A 673.","journal-title":"J Urol"},{"key":"387074_CR56","unstructured":"Solsona Narb\u00f3n E, Gonzalez M, Fernandez J, Pertusa R, Hernandez R, Bernuy C, Unda M, Rabadan M, Martinez-Pineiro L, Nogueira JL, Rodriguez J and members of CUETO group. Random trial comparing intravesical chemo-induction with MMC to immunotherapy with BCG versus intravesical BCG, in patients with intermediate-high risk superficial bladder cancer. Preliminary results of the CUETO trial No. 93009. Eur Urol 2000; (Suppl. 2): A 446."},{"issue":"Suppl.","key":"387074_CR57","first-page":"A 672","volume":"163","author":"O Shahin","year":"2000","unstructured":"Shahin O, Thalmann GN, Bitton A, M\u00f6hrle K, Rentsch C, Studer UE. BCG does not seem to improve recurrence, progression or survival in T1G3 bladder cancer. J Urol 2000; 163(Suppl.): A 672.","journal-title":"J Urol"},{"key":"387074_CR58","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1097\/00005392-199909010-00020","volume":"162","author":"G Dalbagni","year":"1999","unstructured":"Dalbagni G, Rechtschaffen T, Herr HW. Is transurethral biopsy of the bladder necessary after 3 months to evaluate response to bacillus Calmette-Guerin therapy. J Urol 1999; 162: 708\u2013709.","journal-title":"J Urol"},{"key":"387074_CR59","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/j.1464-410X.1989.tb05967.x","volume":"64","author":"BRP Birch","year":"1989","unstructured":"Birch BRP, Harland SJ. The pT1 G3 bladder tumour. Br J Urol 1989; 64: 109\u2013116.","journal-title":"Br J Urol"},{"key":"387074_CR60","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1002\/1097-0142(19920601)69:11<2771::AID-CNCR2820691124>3.0.CO;2-D","volume":"69","author":"H Mameghan","year":"1992","unstructured":"Mameghan H, Fisher RJ, Watt WH, Meagher MJ, Rosen IM, Mameghan J, Brook S, Tynan AP, Korbel EI, Millard RJ. The management of invasive transitional cell carcinoma of the bladder. Results of definitive and preoperative therapy in 390 patients treated at the Prince of Wales Hospital, Sydney, Australia. Cancer 1992; 69: 2771\u20132778.","journal-title":"Cancer"},{"key":"387074_CR61","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1046\/j.1464-410x.1999.00009.x","volume":"83","author":"CRW Bell","year":"1999","unstructured":"Bell CRW, Lydon A, Kernick V, Homg A, Penn C, Pocock RD, Stott MA. Contemporary results of radical radiotherapy for bladder transitional cell carcinoma in a district general hospital with cancer-center status. Br J Urol 1999; 83: 613\u2013618.","journal-title":"Br J Urol"},{"key":"387074_CR62","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/S0094-0143(21)00443-2","volume":"19","author":"MF. Wesson","year":"1992","unstructured":"Wesson MF. Radiation therapy in regionally advanced bladder cancer. Urol Clin North Am 1992; 19: 725\u2013734.","journal-title":"Urol Clin North Am"},{"key":"387074_CR63","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S0094-0143(21)00427-4","volume":"19","author":"MA. Hudson","year":"1992","unstructured":"Hudson MA. When intravesical measures fail - Indications for cystectomy in superficial disease. Urol Clin North Am 1992; 19: 601\u2013609.","journal-title":"Urol Clin North Am"},{"key":"387074_CR64","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1159\/000472824","volume":"13","author":"M St\u00f6ckle","year":"1987","unstructured":"St\u00f6ckle M, Alken P, Engelmann U, Jacobi GH, Riedmiller H, Hohenfellner R. Radical cystectomy - often to late? Eur Urol 1987; 13: 150\u2013152.","journal-title":"Eur Urol"},{"key":"387074_CR65","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0022-5347(17)39544-7","volume":"144","author":"SB Malkowicz","year":"1990","unstructured":"Malkowicz SB, Nichols P, Lieskovsky G, Boyd SD, Huffmann J, Skinner DG. The role of radical cystectomy in the management of high grade superficial bladder cancer (pTa, pT1, Cis and pT2). J Urol 1990; 144: 641\u2013645.","journal-title":"J Urol"},{"issue":"Suppl.","key":"387074_CR66","first-page":"1.5A","volume":"36","author":"A Weber","year":"1997","unstructured":"Weber A, K\u00f6hrmann KU, Hansen S, Alken P. Oberfl\u00e4chliches Harnblasenkarzinom T1G3: Welche Patienten sind Kandidaten f\u00fcr eine Zystektomie. Urologe A 1997; 36(Suppl.): 1.5A.","journal-title":"Urologe A"},{"key":"387074_CR67","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0022-5347(17)34865-6","volume":"151","author":"CL Amling","year":"1994","unstructured":"Amling CL, Thrasher JB, Frazier HA, Dodge RK, Robertson JE, Paulson DF. Radical cystectomy for stages Ta, Tis and T1 transitional cell carcinoma of the bladder. J Urol 1994; 151: 31\u201335.","journal-title":"J Urol"},{"key":"387074_CR68","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0022-5347(17)39675-1","volume":"144","author":"CB Brendler","year":"1990","unstructured":"Brendler CB, Steinberg GD, Marshall FF, Mostwin JL, Walsh PC. Local recurrence and survival following nerve sparing radical cystoprostatectomy. J Urol 1990; 144: 1137\u20131140.","journal-title":"J Urol"},{"key":"387074_CR69","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0094-0143(05)70051-3","volume":"25","author":"MS. Soloway","year":"1998","unstructured":"Soloway MS. Office evaluation and management of bladder neoplasms. Urol Clin North Am 1998; 25: 603\u2013611.","journal-title":"Urol Clin North Am"},{"key":"387074_CR70","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1200\/JCO.1998.16.3.1099","volume":"16","author":"HW. Herr","year":"1998","unstructured":"Herr HW. Extravesical tumor relapse in patients with superfi-cial bladder tumors. J Clin Oncol 1998; 16: 1099\u20131102.","journal-title":"J Clin Oncol"},{"key":"387074_CR71","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1016\/S0022-5347(01)67321-X","volume":"153","author":"S Holmang","year":"1995","unstructured":"Holmang S, Hedelin H, Anderstrom C, Johansson SL. The relationship among multiple recurrences, progression and prognosis of patients with stages Ta and T1 transitional cell cancer of the bladder followed for at least 20 years. J Urol 1995; 153: 1823\u20131826.","journal-title":"J Urol"},{"key":"387074_CR72","first-page":"359","volume":"41","author":"Y Shichiri","year":"1995","unstructured":"Shichiri Y, Kanaba T, Yoshida S, Arai Y. Intravesical instillation of epirubicin hydrochloride in superficial bladder tumor, prophylactic and therapeutic instillation for carcinoma in situ. Hinyokika-Kiyo 1995; 41: 359\u2013364.","journal-title":"Hinyokika-Kiyo"},{"key":"387074_CR73","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0022-5347(01)67606-7","volume":"153","author":"PD Vegt","year":"1995","unstructured":"Vegt PD, Witjes JA, Witjes WP, Doesburg WH, Debruyne FMJ, van der Meijden APM. A randomized study of intravesical mitomycin C, bacillus Calmette-Guerin Tice and bacillus Calmette-Guerin Rivm treatment in pTa-pT1 papillary 40 carcinoma and carcinoma in situ of the bladder. J Urol 1995; 153: 929\u2013933.","journal-title":"J Urol"},{"key":"387074_CR74","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/0090-4295(81)90289-2","volume":"18","author":"RB Bracken","year":"1981","unstructured":"Bracken RB, McDonald MW, Johnson DE. Cystectomy for superficial bladder cancer. Urology 1981; 18: 459\u2013463.","journal-title":"Urology"},{"key":"387074_CR75","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/0090-4295(88)90087-8","volume":"31","author":"LE Siref","year":"1988","unstructured":"Siref LE, Zincke H. Radical cystectomy for historical and pathologic T1, N0, M0 (stage A) transitional cell cancer. Need for adjuvant systemic chemotherapy? Urology 1988; 31: 309\u2013311.","journal-title":"Urology"},{"key":"387074_CR76","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0022-5347(17)38244-7","volume":"145","author":"F Pagano","year":"1991","unstructured":"Pagano F, Bassi P, Galetti TP, Meneghini A, Milani C, Artibani W, Garbeglio. Results of contemporary radical cystectomy for invasive bladder cancer: a clinicopathological study with an emphasis on the inadequacy of the tumor, nodes and metastases classification. J Urol 1991; 145: 45\u201350.","journal-title":"J Urol"},{"key":"387074_CR77","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0022-5347(17)36724-1","volume":"148","author":"MS Cookson","year":"1992","unstructured":"Cookson MS, Sarosdy MF. Management of stage T1 superfi-cial bladder cancer with intravesical bacillus Calmette-Guerin Therapy. J Urol 1992; 148: 797\u2013801.","journal-title":"J Urol"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1014492517088.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1023\/A:1014492517088\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1014492517088.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T05:57:05Z","timestamp":1754891825000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1023\/A:1014492517088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,3]]},"references-count":77,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2002,3]]}},"alternative-id":["387074"],"URL":"https:\/\/doi.org\/10.1023\/a:1014492517088","relation":{},"ISSN":["0301-1623","1573-2584"],"issn-type":[{"value":"0301-1623","type":"print"},{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,3]]}}}